Jun 2014- Tehran- Iran. MELD Center
New therapy for Genotype 3, hopefully, but it is soon to conclude now
Dr Keshvari presented recently published article in management of HCV genotype 3 infection in our discussion meeting.
1- Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001.
2- Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.
In conclusion, in new rea of therapy of HCV infection with new drugs, therapy and eradication of genotype 3 is much more difficult than other genotypes. We should forget the 12 weeks of therapy with Sofosbuvir plus Ribavirin and this strategy should continue for 24 weeks or adding Ledipasvir to Sofosbuvir with 100% of response rate. I believe that before availability of these drugs in our region, it is better to follow the genotype 3 cases with Interferon alpha peg plus ribavirin now.